Table 1.
Demographic and disease characteristics at baseline
| Placebo (N = 83) | Dupilumab (N = 82) | Total (N = 165) | |
|---|---|---|---|
| Age, years | 26·0 (21·0–35·0) | 28·0 (24·0–35·0) | 28·0 (22·0–35·0) |
| Male sex | 60 (72·3) | 58 (70·7) | 118 (71·5) |
| Duration of AD,a years | 12·0 (7·0–20·0) | 13·0 (10·0–22·0) | 13·0 (9·0–21·0) |
| BSA affected by AD, % | 55·0 (40·1–71·0) | 55·0 (35·0–73·5) | 55·0 (39·5–73·0) |
| EASI score | 31·0 (24·5–39·8) | 30·3 (22·8–42·9) | 30·8 (23·3–40·7) |
| IGA score of 4 | 46 (55) | 47 (57) | 93 (56·4) |
| Weekly average of peak daily pruritus NRS scoresb | 8·0 (6·8–9·0) | 8·0 (6·8–8·9) | 8·0 (6·8–9·0) |
| POEM score | 24·0 (20·0–27·0) | 25·0 (21·0–27·0) | 25·0 (20·0–27·0) |
| DLQI score | 18·0 (14·0–23·0) | 18·5 (12·0–22·0) | 18·0 (13·0–23·0) |
AD, atopic dermatitis; BSA, body surface area; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; IQR, interquartile range; NRS, numerical rating scale; POEM, Patient‐Oriented Eczema Measure. aAge at chronic AD diagnosis was calculated as year of chronic AD diagnosis (year of birth + 1). bObtained over the 7‐day period prior to the baseline visit. Data are presented as n (%) or median (IQR).